Patents by Inventor Matthew Nieder

Matthew Nieder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO
    Publication number: 20120129876
    Abstract: The present invention provides novel sulfonylurea salts of a salt of formula (I) and polymorph forms thereof. The compounds in their various forms are effective platelet ADP receptor inhibitors and may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also provides a method for preparing such compounds and forms and for preventing or treating thrombosis and thrombosis related conditions in a mammal comprising the step of administering a therapeutically effective amount of a salt of formula (I) or a pharmaceutically acceptable form thereof.
    Type: Application
    Filed: June 22, 2011
    Publication date: May 24, 2012
    Applicant: Portola Pharmaceuticals, Inc.
    Inventors: Emma Sharp, Louisa Jane Quegan, Anjali Pandey, Juan Wang, Matthew Nieder, Wolin Huang
  • [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO
    Publication number: 20090156620
    Abstract: The present invention provides novel sulfonylurea salts of a salt of formula (I) and polymorph forms thereof. The compounds in their various forms are effective platelet ADP receptor inhibitors and may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also provides a method for preparing such compounds and forms and for preventing or treating thrombosis and thrombosis related conditions in a mammal comprising the step of administering a therapeutically effective amount of a salt of formula (I) or a pharmaceutically acceptable form thereof.
    Type: Application
    Filed: November 5, 2008
    Publication date: June 18, 2009
    Applicant: Portola Pharmaceuticals, Inc.
    Inventors: Emma Sharp, Louisa Jane Quegan, Anjali Pandey, Juan Wang, Matthew Nieder, Wolin Huang
  • [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO
    Publication number: 20090042916
    Abstract: The present invention provides novel sulfonylurea salts of a salt of formula (I) and polymorph forms thereof. The compounds in their various forms are effective platelet ADP receptor inhibitors and may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also provides a method for preparing such compounds and forms and for preventing or treating thrombosis and thrombosis related conditions in a mammal comprising the step of administering a therapeutically effective amount of a salt of formula (I) or a pharmaceutically acceptable form thereof.
    Type: Application
    Filed: May 2, 2008
    Publication date: February 12, 2009
    Applicant: Portola Pharmaceuticals, Inc.
    Inventors: Emma Sharp, Louisa Jane Quegan, Anjali Pandey, Juan Wang, Matthew Nieder, Wolin Huang
  • Tripeptide prodrug compounds
    Publication number: 20070275903
    Abstract: The prodrug of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide of three amino acids, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by a trouase enzyme such as Thimet oligopeptidase. Also disclosed are methods of making and using the prodrug compounds.
    Type: Application
    Filed: March 27, 2007
    Publication date: November 29, 2007
    Applicant: MEDAREX, INC.
    Inventors: Christopher Bebbington, Vincent Dubois, Sanjeev Gangwar, Thomas Lobl, Matthew Nieder, Lesley Pickford, Andre Trouet, Geoffrey Yarranton
  • Prodrug compounds with isoleucine
    Publication number: 20070020694
    Abstract: The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide having an isoleucine residue, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by an enzyme associated with the target cell. Methods of making and using the compounds are also disclosed.
    Type: Application
    Filed: September 29, 2006
    Publication date: January 25, 2007
    Applicant: MEDAREX, INC.
    Inventors: Lesley Pickford, Sanjeev Gangwar, Thomas Lobl, Matthew Nieder, Geoffrey Yarranton
  • CD-10 activated prodrug compounds
    Publication number: 20050267016
    Abstract: The compounds of the invention are modified forms of therapeutic agents. A typical prodrug compound of the invention comprises a therapeutic agent, an oligopeptide, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by the CD10 enzyme. Methods of treatment using the prodrug and methods of designing a prodrug are also disclosed.
    Type: Application
    Filed: December 22, 2004
    Publication date: December 1, 2005
    Applicant: MEDAREX, INC.
    Inventors: Christopher Bebbington, Matthew Nieder, Pina Cardarelli, Sanjeev Gangwar, Lesley Pickford, Chin Pan